杏仁核萎缩量表识别记忆门诊中LATE患者的价值
该回顾性研究纳入日内瓦记忆中心2014—2022年的469名受试者,用杏仁核萎缩量表(AAS)结合阿尔茨海默病(AD)生物标志物分为No-AD/No-LATE、AD、LATE、AD/LATE四组。LATE组表现为轻度遗忘型认知障碍、显著边缘系统萎缩且30个月内认知稳定,AD/LATE组损害最重。
要点
- AAS联合AD生物标志物可在记忆门诊识别LATE,LATE组认知相对稳定。
- AD/LATE组MMSE与情景记忆成绩最差,提示双重病理负担更重。
- 该框架尚需前瞻性与神经病理验证后方可用于临床诊断。
核心结论
- 以AAS结合AD生物标志物识别的LATE患者多表现为轻度遗忘型损害、显著边缘系统萎缩且随访中认知下降缓慢,与既往尸检系列特征一致。
- AD/LATE组较单纯LATE或单纯AD组损害更重。
研究设计与样本
- 回顾性研究,纳入2014—2022年日内瓦记忆中心接受T1加权MRI及临床与神经心理评估的受试者。
- 分析样本469人,平均年龄71.2±8.5岁,53%为女性。
主要发现
- MMSE基线:No-AD/No-LATE组27.9±2.2(N=181),AD组24.2±4.9(N=146),LATE组26.2±3.2(N=36),AD/LATE组22.5±5.3(N=106),p<0.001。
- 自由与线索选择性提醒测验:No-AD/No-LATE组15.1±1.8最高,LATE组13.3±3.5与AD组12.5±4.0相近,均高于AD/LATE组10.6±4.1(p<0.001)。
- LATE与AD/LATE组在TDP-43相关脑区的体积/厚度低于AD与No-AD/No-LATE组。
- 30个月MMSE轨迹:LATE组与No-AD/No-LATE组一样稳定(β=-0.010,95%CI -0.096至0.075,p=0.813)。
- AD组(β=-0.136,95%CI -0.184至-0.088,p<0.001)与AD/LATE组(β=-0.139,95%CI -0.196至-0.082,p<0.001)下降更快。
关键数值与推荐
- AAS评分:AAS0为无萎缩,AAS1为轻至中度萎缩,AAS2为重度萎缩。
- 分组框架:No-AD/No-LATE为AAS0且AD生物标志物阴性,AD为AAS0且阳性,LATE为AAS1-2且阴性,AD/LATE为AAS1-2且阳性。
- 组间比较采用Kruskal-Wallis或χ2检验,脑体积与皮层厚度用协方差分析,认知轨迹用线性混合效应模型并校正基线年龄与教育。
临床怎么用
- 对记忆门诊遗忘型患者可试用AAS联合AD生物标志物分层,识别可能LATE者以判断预后。
- AAS1-2且AD生物标志物阴性者提示LATE,认知下降可能较慢,可据此安排随访强度。
- AAS1-2且AD生物标志物阳性提示AD/LATE,损害更重,需更积极评估与干预。
- 该框架目前仅具研究价值,不能替代神经病理诊断。
局限性
- 为单中心回顾性研究,样本来自日内瓦记忆中心。
- 缺乏神经病理验证,作者指出需前瞻性与神经病理学验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Limbic-predominant age-related TDP-43 encephalopathy (LATE) is a neurodegenerative condition often overlapping clinically with Alzheimer disease (AD). No established in vivo biomarkers exist for LATE. The amygdalar atrophy scale (AAS) is a visual MRI rating tool scoring the amygdala as AAS0 (no atrophy), AAS1 (mild-to-moderate atrophy), or AAS2 (severe atrophy) and is associated with TDP-43 neuropathology in limbic regions. This study describes the clinical, neuroimaging, and longitudinal cognitive profiles of individuals classified using a proposed framework that combines the AAS with established AD biomarkers. METHODS: This retrospective study included individuals attending the Geneva Memory Center (2014-2022) who underwent T1-weighted MRI, as well as clinical and neuropsychological assessments. Participants were categorized with an etiologic grouping defined as No-AD/No-LATE (AAS0, negative AD biomarkers), AD (AAS0, positive AD biomarkers), LATE (AAS1-2, negative AD biomarkers), or AD/LATE (AAS1-2, positive AD biomarkers). Group differences were compared using Kruskal-Wallis or χ2 tests. Differences in MRI brain volumes and cortical thickness between groups were examined with analysis of covariance. Cognitive trajectories using Mini-Mental State Examination (MMSE) scores over 30 months were estimated with linear mixed-effects models accounting for baseline age and education. RESULTS: The analytic sample included 469 participants (mean age 71.2 ± 8.5 years, 53% female). The No-AD/No-LATE group exhibited the highest MMSE scores (N = 181, 27.9 ± 2.2), outperforming AD (N = 146, 24.2 ± 4.9), LATE (N = 36, 26.2 ± 3.2), and AD/LATE (N = 106, 22.5 ± 5.3) groups (p < 0.001). On the Free and Cued Selective Reminding Test, the No-AD/No-LATE group showed the highest scores (15.1 ± 1.8); the LATE and AD groups performed similarly (13.3 ± 3.5 and 12.5 ± 4.0), both exceeding the AD/LATE group (10.6 ± 4.1) (p < 0.001). LATE and AD/LATE groups showed lower volumes/thicknesses in TDP-43-related regions compared with AD and No-AD/No-LATE groups. Longitudinally, the LATE group maintained cognitive stability as the No-AD/No-LATE group (β = -0.010, 95% CI -0.096 to 0.075, p = 0.813), whereas both AD (β = -0.136, 95% CI -0.184 to -0.088, p < 0.001) and AD/LATE (β = -0.139, 95% CI -0.196 to -0.082, p < 0.001) groups showed faster decline over time. DISCUSSION: Patients identified as LATE by the integration of AAS with AD biomarkers had generally mild amnestic cognitive impairment, significant limbic atrophy, and slow decline over time, all features consistent with previous autopsy series. Moreover, AD/LATE cases were more impaired than those with LATE or AD alone. Prospective and neuropathologic validation is warranted.
引用
- Roveta F, Pizzini FB, Natale V, et al. Utility of the Amygdalar Atrophy Scale to Identify Patients With Limbic-Predominant Age-Related TDP-43 Encephalopathy in a Memory Clinic. Neurology. 2025. PMID: 41428981. doi:10.1212/WNL.0000000000214477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。